RFCNU

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585084

CAS#: 56194-22-0

Description: RFCNU is a nitrosourea derivative.

Chemical Structure

img
RFCNU
CAS# 56194-22-0
Instruction

Theoretical Analysis

MedKoo Cat#: 585084
Name: RFCNU
CAS#: 56194-22-0
Chemical Formula: C18H21ClN4O9
Exact Mass: 472.10
Molecular Weight: 472.835
Elemental Analysis: C, 45.72; H, 4.48; Cl, 7.50; N, 11.85; O, 30.45

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: RFCNU

IUPAC/Chemical Name: Urea, N-(2-chloroethyl)-N'-(2,3-O-(1-methylethylidene)-5-O-(4-nitrobenzoyl)ribofuranosyl)-N-nitroso-

InChi Key: YASNUXZKZNVXIS-CBNXCZCTSA-N

InChi Code: InChI=1S/C18H21ClN4O9/c1-18(2)31-13-12(9-29-16(24)10-3-5-11(6-4-10)23(27)28)30-15(14(13)32-18)20-17(25)22(21-26)8-7-19/h3-6,12-15H,7-9H2,1-2H3,(H,20,25)/t12-,13-,14-,15?/m1/s1

SMILES Code: O=C(NC1[C@@H]([C@@H]([C@@H](COC(C2=CC=C([N+]([O-])=O)C=C2)=O)O1)O3)OC3(C)C)N(CCCl)N=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 472.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bourut C, Chenu E, Godenèche D, Madelmont JC, Maral R, Mathé G, Meyniel G. Cytostatic action of two nitrosoureas derived from cysteamine. Br J Pharmacol. 1986 Nov;89(3):539-46. PubMed PMID: 3801787; PubMed Central PMCID: PMC1917164.

2: Andrade Mena CE, Orbach-Arbouys S, Cosmatopoulos K, Mathé G. Effects of three new nitrosourea analogs (CNCC, RFCNU and chlorozotocin) on in vivo destruction of L 1210 leukemia cells and on the immune response. Chemotherapy. 1986;32(2):131-7. PubMed PMID: 2938892.

3: Maral R, Bourut C, Chenu E, Mathe G, Bernon R, Lussan C, Imbach JL, Schein P, Bothorel P. Comparison of the experimental antitumor activities of three nitrosourea derivatives chlorozotocin, RFCNU and CNCC encapsulated in liposomes with those in the free state. Oncology. 1985;42(2):122-8. PubMed PMID: 3157909.

4: Blazsek I, Mathé G, Maral R, Jasmin C. In vivo acute hematotoxicity of N,N'-bis[N-(2-chloroethyl)-N-nitrosocarbamoyl]cystamine (CNCC), a new nitrosourea analog. Toxicol Appl Pharmacol. 1984 Jun 30;74(2):250-7. PubMed PMID: 6740675.

5: Rebischung JL, Gougeon MD, Mori KJ, Lemaigre G, Mathé G, Jasmin C. Hematological toxicity of repeated injections of (chloro-2-ethyl)-ribofuranosyl-3-nitrosourea. Cancer Res. 1984 Feb;44(2):503-6. PubMed PMID: 6692356.

6: Florentin I, Hayat M, Kiger N, Mathé G, Maral J, Imbach JL. Comparative analysis of the immunopharmacological properties of three new nitrosourea analogues: RPCNU, RFCNU and Chlorozotocin. Int J Immunopharmacol. 1983;5(3):201-10. PubMed PMID: 6225736.

7: Madelmont JC, Moreau MF, Godeneche D, Duprat J, Plagne R, Meyniel G. Main metabolites of 1-(2-chloroethyl)-3-[1'-(5'-p-nitrobenzoyl-2',3'-isopropylidene)-alpha, beta-D-ribofuranosyl]-1-nitrosourea and 1-(2-chloroethyl)-3-(2',3', 4'-tri-O-acetyl-alpha, beta-D-ribopyranosyl)-1-nitrosourea in rats. Drug Metab Dispos. 1982 Nov-Dec;10(6):662-6. PubMed PMID: 6130919.

8: Mathé G, Schein PS, De Vassal F, Serrou B, Imbach JL. [Phase II study of 3 new nitrosoureas, 1 American (chlorozotocin) and 2 French (RFCNU and RPCNU)]. Sem Hop. 1982 Sep 16;58(33):1867-71. French. PubMed PMID: 6293062.

9: Mathe G, Schein P, MacDonald JS, Imbach JL, Misset JL, De Vassal F, Ribaud P, Serrou B, Gouveia J, Musset M, Machover D, Schwarzenberg L, Jasmin C, de Jager R. Study of nitrosourea glycosyl analogs--V. An oriented phase II trial of RFCNU. Eur J Cancer Clin Oncol. 1982 Aug;18(8):727-32. PubMed PMID: 6891323.

10: Mathé G, Bothorel P. In vivo enhancement of the experimental oncostatic effect of RFCNU by its encapsulation in liposomes. Biomedicine. 1981 Dec;35(7-8):201-2. PubMed PMID: 7346064.

11: Levallois C, Mani JC, Montero JL, Oiry J, Imbach JL. Action of three nitrosoureas on human lymphocytes. Hypothesis of a specific effect on lymphocyte subpopulations. Farmaco Sci. 1981 Nov;36(11):947-56. PubMed PMID: 7308461.

12: Vlaeminck MN, Collyn-d'Hooghe M, Cappelaere P, Biserte G, Oiry J, Montero JL, Imbach JL. Flow cytofluorometric analysis of the effects of new nitrosourea derivatives on proliferation of EMT 6 tumor cells "in vitro". Biomedicine. 1981 Mar;35(1):27-9. PubMed PMID: 7016209.

13: Mori KJ, Jasmin C, Hayat M, MacDonald JS, Mathé G. In vivo study of acute hematotoxicity of three nitrosoureas, chlorozotocin (chloro-2-ethyl)-ribofuranosyl-3-nitrosourea, and (chloro-2-ethyl)-1-ribopyranosyl-3-nitrosourea. Cancer Res. 1980 Nov;40(11):4282-6. PubMed PMID: 6451285.

14: Godenèche D, Madelmont JC, Moreau MF, Montoloy D, Plagne R. Disposition of the carcinostatic agent 1-(2-chloroethyl)-3-[1'-(5'-p-nitrobenzoyl-2',3'-isopropylidene)-alpha,beta-d-rib ofuranosyl]-1-nitrosourea in animals. Cancer Res. 1980 Sep;40(9):3351-6. PubMed PMID: 7427947.

15: Lemoine R, Gouyette A. Stability and preliminary pharmacokinetic studies of 1-(2-chloroethyl)-3-[1-(5'-paranitrobenzoyl-2',3'-isopropylidene)-alpha, beta-D-ribofuranosyl]-1-nitrosourea (RFCNU), a nonimmunosuppressive nitrosourea. Cancer Treat Rep. 1979 Aug;63(8):1335-41. PubMed PMID: 38907.

16: Meyniel G, Godenech D. [Relationship of labeled molecules in the pharmacokinetic study of alkylating agents (chlorambucil, melphalan, mitoclomine) and glycosyl nitrosoureas (RFCNU and RPCNU)]. Nouv Rev Fr Hematol. 1979;Suppl:XXXIII-XXXV. French. PubMed PMID: 545309.

17: Hayat M, Bourut C, Chenu E, Montero JL, Imbach JL, MacDonald JS, Mathé G. Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice. Cancer Chemother Pharmacol. 1979;3(4):217-21. PubMed PMID: 161207.

18: Mathé G, Serrou B, Hayat M, De Vassal F, Misset JL, Schwarzenberg L, Machover D, Ribaud P, Belpomme D, Jasmin C, Musset M, Montero JL, Imbach JL. Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours. Biomedicine. 1977 Nov;27(8):294-7. French. PubMed PMID: 339971.

19: Imbach JL, Montero JL, Moruzzi A, Serrou B, Chenu E, Hayat M, Mathe G. The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals. Biomedicine. 1975 Dec 20;23(10):410-3. PubMed PMID: 1222217.